<DOC>
	<DOCNO>NCT01003054</DOCNO>
	<brief_summary>The goal clinical research learn treatment high-dose busulfan cyclophosphamide plus autologous bone marrow transplantation follow treatment Gleevec ( imatinib mesylate ) effective treat chronic myelogenous leukemia ( CML ) . Objectives : 1 . To assess efficacy high dose busulfan-cyclophosphamide autologous hematopoietic transplantation post transplant Imatinib mesylate treatment CML . The primary endpoint study determine proportion patient CML alive cytogenetic remission one year follow treatment . 2 . Secondary endpoint time progression survival .</brief_summary>
	<brief_title>Autologous Transplantation Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>Busulfan cyclophosphamide chemotherapy drug design kill leukemia cell . An autologous bone marrow transplant give treatment busulfan cyclophosphamide help recovery blood immune cell treatment . Imatinib mesylate drug help stop growth leukemia cell . It give transplant help kill remain leukemia cell . Before treatment , complete physical exam . You approximately 4 tablespoon blood drawn test check status disease , check organ function , check infectious disease ( hepatitis , HIV , etc. ) . You sample bone marrow collect . To collect bone marrow sample , area hip chest bone numb anaesthetic small amount bone marrow withdrawn large needle . All test do make sure eligible treatment . If find `` blast crisis , '' eligible continue study . If eligible already do recently , take operating room around 4-6 cup bone marrow collect . The procedure perform general anesthesia . The procedure similar bone marrow collection start study , however , bone marrow collect . The bone marrow collect frozen store give back high dose chemotherapy . Before procedure , ask donate blood ( possible ) . This blood give back procedure replace bone marrow collect . You may also need blood transfusion another donor . For patient undergo procedure bone marrow harvest enough bone marrow collect bone marrow harvest procedure , stem cell may collect blood . Normally , stem cell blood . Most bone marrow . To help move `` mobilize '' cell need bone marrow blood , give injection skin day drug call G-CSF . The injection may give nurse hospital , outpatient setting , may learn give injection . Blood sample ( 1 tablespoon ) drawn every day see enough stem cell blood . After 4-6 day treatment G-CSF , undergo procedure call leukapheresis . This procedure similar donate blood blood bank . Blood collect run machine process blood separate cell need transplantation , give rest back . The separated cell frozen store give back high dose chemotherapy . You may need 3 leukapheresis procedure collect enough cell . Patients adequate amount bone marrow blood stem cell harvest past need additional harvesting stem cell . At future time leukemia show sign growth , catheter ( small , flexible tube ) insert collar bone large vein chest . This catheter allow chemotherapy drug , fluid , medication give easily . You approximately 4 tablespoon blood drawn test check status disease , check organ function , check infectious disease ( hepatitis , HIV , etc. ) . You sample bone marrow collect . You also heart ( cardiac ejection fraction ) lung function test . You admit hospital receive high dose chemotherapy . You give busulfan continuous injection ( use catheter ) 4 day , give cyclophosphamide continuous injection ( use catheter ) 2 day . The amount busulfan receive may adjust help decrease risk develop side effect . You may also receive antibiotic , fluid , medication doctor feels necessary . After high dose chemotherapy , give store bone marrow blood stem cell back ( `` transplant '' ) . They give back catheter help restore blood production immunity high dose chemotherapy . To help speed recovery white blood cell , also give G-CSF injection skin daily white blood count recover ( usually 2 3 week ) . You may also receive antibiotic , fluid , medication doctor feels necessary . Blood test repeat several time per week blood count fully recover side effect high dose therapy resolve . After blood count recover , begin treatment imatinib mesylate mouth 1 year . You may also receive medication help prevent infection around 6 month transplant . These medication usually pill help prevent pneumonia viral infection . While take imatinib mesylate blood collect ( 1- 4 tablespoon ) routine test . The frequency blood collection depend medical condition . Around 1 , 3 , 6 , 12 , 18 , 24 month transplant , check-up visit . At visit , blood collect ( 1- 4 tablespoon ) routine blood test sample bone marrow collect test . This bone marrow collection repeat 3 , 4 , 5 year transplant procedure . This investigational study . All drug use study FDA approve commercially available . Up 50 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Criteria hematopoietic stem cell collection cryopreservation : Patients Philadelphia chromosome positive CML &lt; age 70 achieve cytogenetic remission ( Ph+ cell bone marrow cytogenetics , least twenty metaphase count ) eligible hematopoietic stem cell collection cryopreservation . b Patients must Zubrod PS &lt; 2 . c.Creatinine &lt; 1.8 mg/dl d.Serum bilirubin &lt; 1.5 mg/dl e. SGPT &lt; 3 x normal value f. Patients HLA identical sibling eligible refuse allogeneic transplantation . 2 . Patients eligible high dose therapy autologous transplantation meet follow criterion ( numbered 213 ) : Cytogenetic relapse characterize &gt; 10 % Ph+ metaphases ( FISH analysis &gt; 2 20 Ph+ metaphase 2 consecutive cytogenetic study least 1 month apart ) . 3 . Cytogenetic relapse ( ) hematologic remission chronic phase disease , 4 . Accelerated phase second subsequent chronic phase . 5 . Availability store autologous hematopoietic stem cell collect patient cytogenetic complete remission ( 0 &gt; = 20 metaphase positive Ph+ cell ) .A minimum 0.5 x 10 6 CD34 positive cells/kg 1 x 10 8 total nucleated cells/Kg must available . 6 . Age &lt; 70 year . 7 . Zubrod PS &lt; =2 . 8 . Creatinine &lt; 1.8 mg/dL . 9 . Cardiac ejection fraction &gt; 40 % . 10 . DLCO &gt; 50 % predict value . 11 . Serum bilirubin &lt; 1.5 mg/dL . 12 . SGPT &lt; 3 x normal value . 13 . Patients HLA identical sibling eligible refuse allogeneic transplantation . 1 . Uncontrolled lifethreatening infection comorbid condition could impair tolerance regimen . 2 . HIV positivity . 3 . Pregnant lactating woman . 4 . Blast crisis ( &gt; 30 % blast blood marrow ) 5 . Hepatitis B C positivity .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
	<keyword>Stem Cell Transplant</keyword>
</DOC>